Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2020 | Future directions for multiple myeloma treatment

Thomas Martin • 17 Dec 2020
ASH 2020
Multiple Myeloma Antibodies BiTEs Bortezomib CAR-T CC-480 Dexamethasone Iberdomide Lenalidomide Pomalidomide Trastuzumab

Thomas Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, gives an overview of the evolving treatment paradigm for multiple myeloma patients. Dr Martin discusses the potential development of a cure for myeloma in the future, highlighting emerging results from studies investigating CAR T-cell therapies for patients with relapsed/refractory myeloma, and the possible impact of bringing these into a frontline setting. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

Disclosures

Research funding to institution: Sanofi, Janssen, AMGEN
Consultancy: GSK

More from Thomas Martin

4:03
IKEMA long-term sub-group analysis: Isa-Kd for 1q21+ multiple myeloma
Thomas Martin • 11 Sep 2023
2:57
Considerations for mitigating CAR-T resistance in multiple myeloma
Thomas Martin • 11 Sep 2023
4:14
Challenges with the real-world use of CAR-T therapy in multiple myeloma
Thomas Martin • 11 Sep 2023
9:52
Myeloma highlights from SOHO 2023: updates with the use of novel targeted immunotherapies
Thomas Martin • 11 Sep 2023

Related Videos

1:15
Using MRD to guide treatment decisions in myeloma
Karthik Ramasamy • 28 Apr 2024
0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals